⌕
Kazia Therapeutics · KZIA · Nasdaq
Tenet 50 · Mixed
Compare
$5.37−2.19%At closeTenet 50 · Mixed
$5.37−0.12 (−2.19%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

Kazia Therapeutics (KZIA) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is KZIA's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● PRNewsWireNov 19, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026

SYDNEY, Nov. 19, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, today …

KZIA −2.2% todayRead at source ↗
● PRNewsWireNov 12, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Kazia Therapeutics to Host Virtual Event on December 2, 2026: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein Degrader

SYDNEY, Nov. 12, 2026 /PRNewswire/ -- Kazia Therapeutics Limited  (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, resto…

KZIA −2.2% todayRead at source ↗
● Defense WorldNov 11, 2026 · 01:15 ET
Novogen Limited (NASDAQ:KZIA) Stock Has Consensus Price Target of $29.50

Shares of Novogen Limited (NASDAQ: KZIA - Get Free Report) have earned a consensus rating of "Moderate Buy" from the nine brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock wi…

KZIA −2.2% todayRead at source ↗
● PRNewsWireNov 5, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards

Recognition Highlights Kazia's Focus on Overcoming Treatment Resistance in Cancer SYDNEY, Nov. 5, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnolo…

KZIA −2.2% todayRead at source ↗
● PRNewsWireNov 2, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium

Presentations to Explore Paxalisib's Differentiated Tumor and Immune Reprogramming Activity SYDNEY, Nov. 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused b…

KZIA −2.2% todayRead at source ↗
● PRNewsWireOct 29, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference

SYDNEY, Oct. 29, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and o…

KZIA −2.2% todayRead at source ↗
● PRNewsWireSep 22, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia SYDNEY, Sept. 22, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechno…

KZIA −2.2% todayRead at source ↗
● PRNewsWireSep 9, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies currently exist SYDNEY, Sept. 9, 2026 /PRNewswire/ -- Kazia Therapeu…

KZIA −2.2% todayRead at source ↗
● Seeking AlphaSep 4, 2026 · 18:19 ET
Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer Transcript

Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer Transcript…

KZIA −2.2% todayRead at source ↗
● PRNewsWireSep 1, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and…

KZIA −2.2% todayRead at source ↗
● PRNewsWireSep 1, 2026 · 07:15 ETCOMPANY'S OWN WORDS
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer

Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity Three-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib Plu…

KZIA −2.2% todayRead at source ↗
● PRNewsWireAug 31, 2026 · 17:58 ETCOMPANY'S OWN WORDS
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering

Company to host a corporate update call Tuesday, September 1st at 8:00am ET SYDNEY, Aug. 31, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology co…

KZIA −2.2% todayRead at source ↗
● Seeking AlphaAug 31, 2026 · 08:15 ET
Kazia Therapeutics: Worth Speculating On Paxalisib's TNBC Data

Kazia's first 6 TNBC patients all achieved clinical benefits. These early results make paxalisib a much more promising asset going forward. Responses across visceral, skeletal, and CNS metastases make that early signal m…

KZIA −2.2% todayRead at source ↗
● PRNewsWireAug 28, 2026 · 07:30 ET
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering

SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restor…

KZIA −2.2% todayRead at source ↗
● PRNewsWireAug 27, 2026 · 16:09 ET
Kazia Therapeutics Limited Announces Proposed Public Offering

SYDNEY, Aug. 27, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restor…

KZIA −2.2% todayRead at source ↗
● PRNewsWireAug 27, 2026 · 16:01 ET
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer

Durable Complete Metabolic Response Ongoing Since November 2025 All Evaluable Patients Demonstrated Reductions in Metastasis-Associated CTC Clusters and Terminally Exhausted T cells, With Median Reductions of 83% and 51%…

KZIA −2.2% todayRead at source ↗
● Seeking AlphaAug 27, 2026 · 08:59 ET
Kazia Therapeutics: Upcoming Data May Validate Best-In-Class Potential Of Paxalisib

Kazia Therapeutics is rated Strong Buy, driven by best-in-class potential for paxalisib and a discounted valuation. Paxalisib has shown strong efficacy in triple-negative breast cancer, including a complete response in a…

KZIA −2.2% todayRead at source ↗

No upcoming events in the feeds.

ANT13−7.0%
AAPL8+0.3%
FOX6−2.9%
META6−2.2%

Article counts from the last market-wide feed page, across every symbol we track and not just KZIA · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.